Opthea’s Phase 2b Results of OPT-302 Combo Therapy Published in Ophthalmology: A Promising Treatment for Wet AMD
Opthea Limited, a clinical-stage biopharmaceutical company, has disclosed that the Phase 2b clinical trial results of OPT-302, their anti-VEGF-C/-D "trap" agent given together with Lucentis® (ranibizu ...
FDA Approves Apellis’ SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy (GA)
Apellis Pharmaceuticals, Inc. announced today that SYFOVRE™ (pegcetacoplan injection) has been approved by the United States Food and Drug Administration (FDA) for the treatment of geographic atrophy ...